-
Media Release
Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
-
Media Release
Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)
-
Media Release
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Media Release
Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US
-
Media Release
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
-
Story
What Are GTTs? These Technologies Can Impact How a Gene Functions -
Story
A Breakthrough for Patients: 25 Year Anniversary of Innovation in Treating CML -
Story
Five Questions with Reshema Kemps-Polanco, Novartis US Chief Commercial Officer -
Story
Novartis in San Diego: A Quarter Century of R&D Innovation -
Story
Designing for the Future: The Next Era of Biomedical Research in San Diego -
Media Release
Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure
-
Media Release
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren's disease